Skip to main content
. Author manuscript; available in PMC: 2021 Jun 12.
Published in final edited form as: Cell Rep. 2021 Jan 5;34(1):108574. doi: 10.1016/j.celrep.2020.108574

Figure 4. SALL4 and Heterochromatin.

Figure 4.

(A) Western blotting of SNU398 liver cancer cell lysates at 40 h after SALL4 KD with gel cut for clarity; molecular weight marker is indicated on the right (left panel); Kd, kilodalton; summary of western blot densitometry from two separate SALL4 KD experiments of H3K9me2/3 protein expression (black bars) and KDM3A expression (gray bars) (right panel).

(B) Western blotting of SNU398 cell lysates collected after either control DMSO or pomalidomide (Pom; 10 μM) treatments at the indicated time points.

(C) Immunofluorescence staining of HP1 of SNU398 liver cancer cells transduced with SCR control or two shRNAs against SALL4; white scale bar denotes 33 μm; DAPI, 4’,6-diamidino-2-phenylindole DNA stain.